Contact
searchSearch
HMP Global
Login

HER2-Low Breast Cancer Specialty Channel

Conference Coverage
HER2-Low Breast Cancer in the National Cancer Database
12/09/2022
Katie Herman
Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.
Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.
Daniel Peiffer, MD, PhD, and...
12/09/2022
Journal of Clinical Pathways
Conference Coverage
HER2-Positive Metastatic Breast Cancer Treatment Patterns in Patients Who Have Received at Least Two Lines of Therapy
12/07/2022
Katie Herman
Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.
Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.
Della Varghese, PharmD, PhD, and...
12/07/2022
Journal of Clinical Pathways
Conference Coverage
Clinical and Pathological Differences in Breast Cancer Patients With HER2-low and Other Cancer Subtypes
12/07/2022
Katie Herman
Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.
Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.
Andre Mattar, MD, PhD, and...
12/07/2022
Journal of Clinical Pathways
Naoto Ueno, MD
Videos
Progression-Free Survival Associated With Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
10/20/2022
In an interview exploring the progression-free survival and overall survival among patients with HER2-low metastatic breast cancer who received one or two previous lines of chemotherapy, Naoto Ueno, MD, highlights the impacts that trastuzumab...
In an interview exploring the progression-free survival and overall survival among patients with HER2-low metastatic breast cancer who received one or two previous lines of chemotherapy, Naoto Ueno, MD, highlights the impacts that trastuzumab...
In an interview exploring the...
10/20/2022
Journal of Clinical Pathways
Sayeh Lavasani, MD, MS, FRCPC
Videos
Utilizing Pathways to Mitigate Costs in Metastatic Breast Cancer Treatment
10/16/2022
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC,...
10/16/2022
Journal of Clinical Pathways
News
State Legislative Trends in Biomarker Testing
09/20/2022
Yvette C. Terrie, BS Pharm, RPh
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that...
09/20/2022
Journal of Clinical Pathways
Sara Tolaney, MD, MPH
Videos
Factors Associated With a Greater Risk of Treatment Discontinuation in High-Risk Early Breast Cancer
08/03/2022
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses...
08/03/2022
Journal of Clinical Pathways
Shlomit Amar-Farkash, PhD, MSc
Videos
Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer
07/14/2022
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc,...
07/14/2022
Journal of Clinical Pathways
News
Guideline Update on Use of Biomarkers for Adjuvant Endocrine and Chemotherapy in Breast Cancer
07/08/2022
Ellen Kurek
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the...
07/08/2022
Journal of Clinical Pathways
Debra Patt, MD, PhD, MBA, Texas Oncology, US Oncology Network
Videos
Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer
07/06/2022
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA,...
07/06/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib
12/07/2021
Janelle Bradley
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients...
12/07/2021
Journal of Clinical Pathways

Expert Insights

Naoto Ueno, MD
Videos
Progression-Free Survival Associated With Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
10/20/2022
In an interview exploring the progression-free survival and overall survival among patients with HER2-low metastatic breast cancer who received one or two previous lines of chemotherapy, Naoto Ueno, MD, highlights the impacts that trastuzumab...
In an interview exploring the progression-free survival and overall survival among patients with HER2-low metastatic breast cancer who received one or two previous lines of chemotherapy, Naoto Ueno, MD, highlights the impacts that trastuzumab...
In an interview exploring the...
10/20/2022
Journal of Clinical Pathways
Sayeh Lavasani, MD, MS, FRCPC
Videos
Utilizing Pathways to Mitigate Costs in Metastatic Breast Cancer Treatment
10/16/2022
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC,...
10/16/2022
Journal of Clinical Pathways
Sara Tolaney, MD, MPH
Videos
Factors Associated With a Greater Risk of Treatment Discontinuation in High-Risk Early Breast Cancer
08/03/2022
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses...
08/03/2022
Journal of Clinical Pathways
Shlomit Amar-Farkash, PhD, MSc
Videos
Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer
07/14/2022
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc,...
07/14/2022
Journal of Clinical Pathways
Debra Patt, MD, PhD, MBA, Texas Oncology, US Oncology Network
Videos
Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer
07/06/2022
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...
Debra Patt, MD, PhD, MBA,...
07/06/2022
Journal of Clinical Pathways
Ethan Sokol, PhD
Videos
Real-World Outcomes of HR-Positive HER2-Negative Metastatic Breast Cancer Treated With ICIs
10/21/2021
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses...
10/21/2021
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
04/24/2025
Lalan Wilfong, MD
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
04/24/2025
Journal of Clinical Pathways
Videos
Confronting Intersectional Stigmas Across the Cancer Care Continuum
04/24/2025
Gretchen McNally, PhD, MPH, discusses how intersectional stigmas—rooted in social biases around race, gender, socioeconomic status, and other identities—negatively affect cancer care across the continuum, influencing treatment access,...
Gretchen McNally, PhD, MPH, discusses how intersectional stigmas—rooted in social biases around race, gender, socioeconomic status, and other identities—negatively affect cancer care across the continuum, influencing treatment access,...
Gretchen McNally, PhD, MPH,...
04/24/2025
Journal of Clinical Pathways
Oncology Innovations
Videos
Strengthening Pathway-Driven Care Through Payer Collaboration
04/23/2025
Gordon Kuntz; Lalan Wilfong, MD
In this episode of Oncology Innovations, Gordon Kuntz and Dr Lalan Wilfong discusses the evolving role of payers and value-based care intermediaries in oncology, emphasizing the importance of whole-person support, coordinated care, and...
In this episode of Oncology Innovations, Gordon Kuntz and Dr Lalan Wilfong discusses the evolving role of payers and value-based care intermediaries in oncology, emphasizing the importance of whole-person support, coordinated care, and...
In this episode of Oncology...
04/23/2025
Journal of Clinical Pathways
Steven Monda, MD
Videos
Evaluating the Performance of Biomarkers from Metastatic vs Primary Sites in Clear Cell Renal Cell Carcinoma
04/23/2025
Steven Monda, MD
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his...
04/23/2025
Journal of Clinical Pathways
Hafron Headshot
Videos
Developing a National Pathway Framework for Prostate Cancer: Insights from Solaris Health
04/17/2025
Jason Hafron, MD
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how...
04/17/2025
Journal of Clinical Pathways
Adam Brufsky, MD
Interview
The Overall Cost-Effectiveness of Adjuvant Ribociclib in ER+ Early Breast Cancer
04/15/2025
Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD, discusses how adjuvant ribociclib may offer long-term value in early estrogen-receptor-positive (ER+) breast cancer by reducing costly recurrences, despite its upfront expense.
Adam Brufsky, MD, PhD, discusses how adjuvant ribociclib may offer long-term value in early estrogen-receptor-positive (ER+) breast cancer by reducing costly recurrences, despite its upfront expense.
Adam Brufsky, MD, PhD, discusses...
04/15/2025
Journal of Clinical Pathways
Figlin
Videos
Durable Responses With Belzutifan Plus Cabozantinib in Advanced RCC: Updated Findings From LITESPARK-003
04/15/2025
Robert A. Figlin, MD
In this interview, Dr Robert Figlin discusses the promising clinical activity of belzutifan combined with cabozantinib in advanced clear cell renal cell carcinoma, highlighting its potential role in future treatment pathways, practical...
In this interview, Dr Robert Figlin discusses the promising clinical activity of belzutifan combined with cabozantinib in advanced clear cell renal cell carcinoma, highlighting its potential role in future treatment pathways, practical...
In this interview, Dr Robert...
04/15/2025
Journal of Clinical Pathways
Speicher headshot
Videos
Building Smarter Pathways: How AI Can Support Precision Oncology Within a Regulatory Framework
04/11/2025
Dr Stephen Speicher highlights how evolving AI regulations, clinician collaboration, and transparent, human-centered frameworks are critical to safely integrating AI into oncology care pathways and enhancing decision-making at the point of...
Dr Stephen Speicher highlights how evolving AI regulations, clinician collaboration, and transparent, human-centered frameworks are critical to safely integrating AI into oncology care pathways and enhancing decision-making at the point of...
Dr Stephen Speicher highlights...
04/11/2025
Journal of Clinical Pathways
Sahana Somasegar
Interview
Rethinking Immunotherapy: A Case for Personalization in Advanced Endometrial Cancer
04/11/2025
A guest researcher shares a compelling case study that challenges conventional assumptions about immunotherapy in endometrial cancer, revealing how personalized treatment and multidisciplinary care enabled long-term disease control despite...
A guest researcher shares a compelling case study that challenges conventional assumptions about immunotherapy in endometrial cancer, revealing how personalized treatment and multidisciplinary care enabled long-term disease control despite...
A guest researcher shares a...
04/11/2025
Journal of Clinical Pathways
Videos
EV-302 Follow-Up Reinforces Shift in Frontline Urothelial Cancer Pathways
04/10/2025
Thomas Powles, MBBS, MD
In this interview, Dr Tom Powles discusses how updated results from the EV-302 trial confirm that enfortumab vedotin plus pembrolizumab significantly improves survival and response rates compared to standard chemotherapy in first-line...
In this interview, Dr Tom Powles discusses how updated results from the EV-302 trial confirm that enfortumab vedotin plus pembrolizumab significantly improves survival and response rates compared to standard chemotherapy in first-line...
In this interview, Dr Tom Powles...
04/10/2025
Journal of Clinical Pathways

Newsfeed

Conference Coverage
HER2-Low Breast Cancer in the National Cancer Database
12/09/2022
Katie Herman
Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.
Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.
Daniel Peiffer, MD, PhD, and...
12/09/2022
Journal of Clinical Pathways
Conference Coverage
HER2-Positive Metastatic Breast Cancer Treatment Patterns in Patients Who Have Received at Least Two Lines of Therapy
12/07/2022
Katie Herman
Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.
Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.
Della Varghese, PharmD, PhD, and...
12/07/2022
Journal of Clinical Pathways
Conference Coverage
Clinical and Pathological Differences in Breast Cancer Patients With HER2-low and Other Cancer Subtypes
12/07/2022
Katie Herman
Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.
Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.
Andre Mattar, MD, PhD, and...
12/07/2022
Journal of Clinical Pathways
News
State Legislative Trends in Biomarker Testing
09/20/2022
Yvette C. Terrie, BS Pharm, RPh
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that...
09/20/2022
Journal of Clinical Pathways
News
Guideline Update on Use of Biomarkers for Adjuvant Endocrine and Chemotherapy in Breast Cancer
07/08/2022
Ellen Kurek
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the...
07/08/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib
12/07/2021
Janelle Bradley
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Budget Impact of Blood-Based Biomarker Assay in Patients With Metastatic Breast Cancer
12/07/2021
Janelle Bradley
Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...
Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...
Use of a blood-based biomarker...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting
12/07/2021
Janelle Bradley
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases
12/06/2021
Janelle Bradley
Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.
Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.
Palbociclib plus letrozole is...
12/06/2021
Journal of Clinical Pathways
Conference Coverage
Recent Advancements in Biomarker Testing and Therapeutic Strategies in Oncology
05/03/2021
05/03/2021
Journal of Clinical Pathways
News
EHR-Based Model Accurately Identifies High-Risk Patients for Gastric Cancer
04/24/2025
Lisa Kuhns, PhD, MD
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record...
04/24/2025
Journal of Clinical Pathways
News
Myelofibrosis Symptom Assessment Tool Demonstrates Strong Validity and Reliability in Trials
04/15/2025
Lisa Kuhns, PhD, MD
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom...
04/15/2025
Journal of Clinical Pathways
News
Study Links Breast Cancer Screening Rates to Social Determinants and Access to Mammography Services
04/11/2025
Hannah Musick
A nationwide study found that breast cancer screening rates are strongly influenced by social determinants and local access to mammography, with higher rates linked to education, facility proximity, and racial demographics.
A nationwide study found that breast cancer screening rates are strongly influenced by social determinants and local access to mammography, with higher rates linked to education, facility proximity, and racial demographics.
A nationwide study found that...
04/11/2025
Journal of Clinical Pathways
News
New Risk Model Enhances Prognostic Precision in Mantle Cell Lymphoma
04/10/2025
Danielle Sposato
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study...
04/10/2025
Journal of Clinical Pathways
News
Health Care Burden Associated With Anemia in Ruxolitinib-Treated Myelofibrosis
04/08/2025
Juliet Gallagher
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using...
04/08/2025
Journal of Clinical Pathways
News
Survival in Mantle Cell Lymphoma Improves With Shifts in Treatment Patterns
04/07/2025
Hannah Musick
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients...
04/07/2025
Journal of Clinical Pathways
News
Predicting HER2 Expression in Gastric Cancer With a Deep Learning Model
04/07/2025
Juliet Gallagher
A recent study published in Advanced Science has introduced a deep learning model called HER2Net, which predicts HER2 status in gastric cancer (GC) using hematoxylin-eosin (H&E)–stained pathology slides.
A recent study published in Advanced Science has introduced a deep learning model called HER2Net, which predicts HER2 status in gastric cancer (GC) using hematoxylin-eosin (H&E)–stained pathology slides.
A recent study published in...
04/07/2025
Journal of Clinical Pathways
News
Financial Strain Persists for Patients With Cancer Despite Support Referrals
04/04/2025
Grace Taylor, MS, MA
Despite targeted support, patients with cancer face ongoing and emerging financial toxicity and health-related social risks, underscoring the need for more sustainable interventions.
Despite targeted support, patients with cancer face ongoing and emerging financial toxicity and health-related social risks, underscoring the need for more sustainable interventions.
Despite targeted support,...
04/04/2025
Journal of Clinical Pathways
Conference Coverage
Delayed EGFR Testing in Early-Stage NSCLC Linked to Increased Health Care Utilization and Cost Burden
04/01/2025
Juliet Gallagher
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
Study Explores Early Palliative Care Referral Patterns and Outcomes in SCLC
04/01/2025
Juliet Gallagher
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National...
04/01/2025
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use